ClinicalTrials.gg
RecruitingNCT07574385Updated May 7, 2026

Sciatic Nerve Block With ALX006 in Subjects Undergoing Bunionectomy

A Phase 2 interventional study of ALX006 (bupivacaine extended-release injection) and Bupivacaine Hcl 0.25% Inj in Hallux Valgus and Bunionectomy, sponsored by Rebel Medicine Inc. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-07.

Sponsored by Rebel Medicine Inc · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Aug 2026, 3 months ago, but the record still lists the study as recruiting.
  • Started Mar 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 32 studies in Hallux Valgus with a site in United States — 5 open to participants now, 7 under way, 1 of them phase 3. Hallux Valgus · United States.

Planned enrollment
16th of 24
60 · median 86
Started
2026
with 2 others
Phase 2
3 of 32
1 open now
Registered
31st of 32
by date

Among the 32 studies in Hallux Valgus with a site in United States, this one is the 16th largest by planned enrollment of the 24 interventional ones that give a count, is one of 3 that started in 2026, is one of 3 in phase 2, and was the 31st registered.

Hallux Valgus

157 studies on the registry are indexed under Hallux Valgus; 36 are open to participants now.

Browse Hallux Valgus studies →

Open to participants now

5 of the 32 studies in Hallux Valgus with a site in United States are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 21 Hallux Valgus studies recruiting now, 10 (48%) set no upper age limit and 7 (33%) stop at 75 or younger; 3 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Hallux Valgus with a site in United States, or all of them as a file.
02

Study summary

This is a Phase 2, randomized, double-blind, active-controlled, dose-escalation study evaluating the safety, pharmacokinetics, efficacy, and pharmacodynamics of ALX006, an extended-release bupivacaine formulation, administered as a single-dose sciatic nerve block in the popliteal fossa in adult subjects undergoing primary unilateral bunionectomy. Approximately 60 subjects will be enrolled across 3 sequential dose cohorts (100 mg, 150 mg, 200 mg ALX006), with each cohort comparing ALX006 against MARCAINE 0.25% (bupivacaine HCl 50 mg) as the active comparator at a 3:1 randomization ratio. Dose escalation between cohorts is governed by an Independent Data Monitoring Committee.

03

Conditions studied

  • Hallux Valgus
  • Bunionectomy

Browse trials for

Keywords

  • ALX006
  • Bupivacaine
  • Popliteal fossa nerve block
  • Analgesia
  • Post-operative analgesia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female, ages 18 or older at screening
  • (ASA) physical status 1, 2, or 3 (see Appendix 5)
  • Able to provide , adhere to the study schedule, and complete all study assessments
  • Primary surgical indication is related to a bunion deformity (i.e., hallux valgus) and subject is scheduled to undergo a primary unilateral distal metaphyseal osteotomy procedure (i.e., Austin procedure)
  • Indicated to undergo elective (i.e., not emergency) bunionectomy
  • (BMI) ≥18 and \<40 kg/m2

Exclusion criteria

Exclusion Criteria:

  • Allergy, , intolerance, or to any of the study medications for which an alternative is not named in the protocol (e.g., amide-type local anesthetics, opioids, bupivacaine HCl, NSAIDs)
  • Concurrent painful physical condition (e.g. arthritis, fibromyalgia, cancer) that may require analgesic treatment with NSAIDs or opioids in the post dosing period for pain that is not strictly related to the surgery and which, in the Investigator's opinion, may confound the post dosing assessments
  • Inadequate sensory function of the foot/ankle as assessed by the Investigator
  • History of, suspected, or known addiction to or abuse of illicit drug(s), prescription medicine(s), or alcohol within the past two (2) years
  • Administration of an drug within thirty (30) days or five (5) elimination half-lives of such investigational drug, whichever is longer, prior to study drug administration, or planned administration of another investigational product or procedure during the subject's participation in this study
  • Administration of any local anesthetic within 72 hours prior to administration of study drug, other than for pretreatment prior to a needle placement
  • Require additional local anesthetic other than study drug or lidocaine used for the Mayo field block or for pretreatment prior to a needle placement during the study period
  • Uncontrolled anxiety, psychiatric, or neurological disorder that, in the opinion of the Investigator, could interfere with study assessments or compliance
  • Currently pregnant, nursing, or planning to become pregnant during the study
  • medical disease that, in the opinion of the Investigator would make participation in a clinical study inappropriate. This includes diabetic neuropathy, coagulation or bleeding disorders, severe peripheral vascular disease, renal insufficiency, hepatic dysfunction, glucose-6-phosphate dehydrogenase deficiency or other conditions that would constitute a contraindication to participation in the study
  • Confirmed clinically significant vital sign or abnormality, including > 450 msec at Screening
  • Has any of the following laboratory abnormalities during Screening (1 retest permitted):

    1. History of liver cirrhosis, having an >3x the (ULN), or having an alanine aminotransferase > 3x ULN.
    2. Severe kidney function impairment as defined by estimated (eGFR) by CKD-EPI 2021 equation \<30 mL/min/1.73 m²or on dialysis.
    3. count \< 100,000/uL, \< 12 g/dL, or hematocrit \< 35%.
  • Currently on a gabapentinoid (e.g., gabapentin, pregabalin [Lyrica]) or a serotonin-norepinephrine reuptake inhibitor (SNRI) with recognized analgesic properties (e.g., duloxetine [Cymbalta]) that cannot be discontinued within 30 days before surgery. Other agents with documented efficacy in modulating acute or chronic pain may be excluded at the discretion of the Investigator in consultation with the Sponsor Medical Monitor. Selective serotonin reuptake inhibitors (SSRIs) are not excluded under this criterion.
  • Current use of systemic within thirty (30) days of randomization in this study
  • Use of dexmedetomidine HCl or clonidine within three (3) days of study drug administration
  • Any use of marijuana (including tetrahydrocannabinol (THC) and cannabidiol (CBD)) within thirty (30) days prior to randomization, or planned use during the study.
  • Chronic opioid use within thirty (30) days prior to randomization (average ≥30 oral morphine mg equivalents/day)
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    ALX006 100 mg

    Single-dose ALX006 100 mg (50 mg/mL bupivacaine free base) administered as ultrasound-guided sciatic nerve block in the popliteal fossa, 60 min (±15 min) prior to bunionectomy.

    Drug: ALX006 (bupivacaine extended-release injection) · Procedure: Sciatic Nerve Block

  • Experimental
    ALX006 150 mg

    Single-dose ALX006 150 mg (50 mg/mL bupivacaine free base) administered as ultrasound-guided sciatic nerve block in the popliteal fossa, 60 min (±15 min) prior to bunionectomy.

    Drug: ALX006 (bupivacaine extended-release injection) · Procedure: Sciatic Nerve Block

  • Experimental
    ALX006 200 mg

    Single-dose ALX006 200 mg (50 mg/mL; bupivacaine free base) administered as ultrasound-guided sciatic nerve block in the popliteal fossa, 60 min (±15 min) prior to bunionectomy.

    Drug: ALX006 (bupivacaine extended-release injection) · Procedure: Sciatic Nerve Block

  • Active comparator
    MARCAINE 0.25%

    Single-dose MARCAINE 0.25% (bupivacaine HCl 50 mg; 20 mL), administered as ultrasound-guided sciatic nerve block in the popliteal fossa, 60 min (±15 min) prior to bunionectomy.

    Drug: Bupivacaine Hcl 0.25% Inj · Procedure: Sciatic Nerve Block

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence and severity of treatment-emergent adverse events (TEAEs)

    TEAEs graded by CTCAE v5.0, summarized by System Organ Class and Preferred Term

    Time frame: From start of nerve block procedure through 360 Hour Visit (Day 15)

Secondary outcomes

  1. AUC of NRS pain intensity scores 0-72 hours post-surgery

    Area under the curve of 11-point Numeric Rating Scale (0 = no pain; 10 = worst possible pain) for current pain in operative foot

    Time frame: 0 to 72 hours post-surgery

  2. AUC of NRS pain intensity scores 0-96 hours post-surgery

    Area under the curve of 11-point Numeric Rating Scale (0 = no pain; 10 = worst possible pain) for current pain in operative foot

    Time frame: 0 to 96 hours post-surgery

  3. AUC of NRS pain intensity scores 0-120 hours post-surgery

    Area under the curve of 11-point Numeric Rating Scale (0 = no pain; 10 = worst possible pain) for current pain in operative foot

    Time frame: 0 to 120 hours post-surgery

  4. Total postsurgical opioid consumption in oral morphine equivalents (OMED) from 0 to 72 hours post-surgery

    Cumulative opioid consumption from the end of surgery through 72 hours, calculated as oral morphine equivalent dose (OMED) using CDC opioid morphine equivalent conversion factors.

    Time frame: 0 to 72 hours post-surgery

  5. Total postsurgical opioid consumption in oral morphine equivalents (OMED) from 0 to 96 hours post-surgery

    Cumulative opioid consumption from the end of surgery through 96 hours, calculated as oral morphine equivalent dose (OMED) using CDC opioid morphine equivalent conversion factors.

    Time frame: 0 to 96 hours post-surgery

  6. Total postsurgical opioid consumption in oral morphine equivalents (OMED) from 0 to 120 hours post-surgery

    Cumulative opioid consumption from the end of surgery through 120 hours, calculated as oral morphine equivalent dose (OMED) using CDC opioid morphine equivalent conversion factors.

    Time frame: 0 to 120 hours post-surgery

  7. Percentage of opioid-free subjects through 72 hours post-surgery

    Proportion of subjects who consumed no opioid medication from the end of surgery through 72 hours.

    Time frame: 0 to 72 hours post-surgery

  8. Percentage of opioid-free subjects through 96 hours post-surgery

    Proportion of subjects who consumed no opioid medication from the end of surgery through 96 hours.

    Time frame: 0 to 96 hours post-surgery

  9. Percentage of opioid-free subjects through 120 hours post-surgery

    Proportion of subjects who consumed no opioid medication from the end of surgery through 120 hours.

    Time frame: 0 to 120 hours post-surgery

  10. Median time to first postsurgical opioid consumption

    Time from end of surgery to administration of the first postsurgical opioid dose.

    Time frame: End of surgery through 168 hours post-surgery

  11. Plasma bupivacaine maximum observed concentration (Cmax)

    Maximum observed plasma bupivacaine concentration following single-dose administration

    Time frame: Pre-dose through 168 hours post-block administration

  12. Time to maximum plasma bupivacaine concentration (Tmax)

    Time from end of block administration to the maximum observed plasma bupivacaine concentration.

    Time frame: Pre-dose through 168 hours post-block administration

  13. Apparent terminal elimination half-life of bupivacaine (t½el)

    Apparent terminal elimination half-life of plasma bupivacaine

    Time frame: Pre-dose through 168 hours post-block administration

  14. Apparent clearance of bupivacaine (CL/F)

    Apparent clearance of bupivacaine following perineural administration, derived by non-compartmental analysis.

    Time frame: Pre-dose through 168 hours post-block administration

Other outcomes

  1. Median time to onset of sensory block

    Median time from end of block administration to the earliest timepoint with loss of light touch sensation along the distribution of the target nerve distal to the block site

    Time frame: From end of block administration through 168 hours

  2. Median duration of sensory block

    Median time between onset and offset of sensory block, where offset is defined as the first timepoint of return of light touch sensation in both test areas in a single assessment.

    Time frame: From end of block administration through 168 hours

  3. Median time to onset of motor block

    Median time from end of block administration to the earliest timepoint with partial or no foot movement

    Time frame: From end of block administration through 168 hours

  4. Median duration of motor block

    Median time between onset and offset of motor block, where offset is defined as resolution of motor block with complete foot movement (dorsiflexion and plantar flexion)

    Time frame: From end of block administration through 168 hours

07

Study locations

1 of 1 sites recruiting
  • CenExel Salt Lake City
    Millcreek, Utah 84107, United States
    Recruiting
    • Director of Clinical Operations · Contacts.zunkowski@cenexel.com · (801) 261-2000
    • Todd Bertoch, MD · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2026 (actual). Primary completion is estimated for Aug 2026, 5 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 28, 2026
First posted
May 7, 2026
StartActual
Mar 10, 2026
Primary completionEst.
Aug 2026
CompletionEst.
Aug 2026
Last update
May 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07574385
Lead sponsor
Rebel Medicine Inc
Responsible party
Sponsor
First posted
May 7, 2026
Start date
Mar 10, 2026
Primary completion
Aug 2026 (estimated)
Completion
Aug 2026 (estimated)
Last update
May 7, 2026

Study contacts

Caleb Lade, MD
Contact
caleb.lade@rebelmedicine.com
918-808-8399
Jayant Agarwal, MD
study director · Rebel Medicine Inc

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bupivacaine

Start the discussion